Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 1.17 and has seen 1.34 million shares traded in the last trading session. The company, currently valued at $1.09B, closed the last trade at $9.35 per share which meant it lost -$0.39 on the day or -4.00% during that session. The ARQT stock price is -40.86% off its 52-week high price of $13.17 and 81.18% above the 52-week low of $1.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.51 million shares traded. The 3-month trading volume is 2.04 million shares.
The consensus among analysts is that Arcutis Biotherapeutics Inc (ARQT) is Buy stock at the moment, with a recommendation rating of 1.29. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Sporting -4.00% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ARQT stock price touched $9.35 or saw a rise of 5.27%. Year-to-date, Arcutis Biotherapeutics Inc shares have moved 189.47%, while the 5-day performance has seen it change -3.41%. Over the past 30 days, the shares of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have changed -7.97%. Short interest in the company has seen 27.13 million shares shorted with days to cover at 14.56.
Wall Street analysts have a consensus price target for the stock at $27.5, which means that the shares’ value could jump 66.0% from current levels. The projected low price target is $18.0 while the price target rests at a high of $51.0. In that case, then, we find that the current price level is -445.45% off the targeted high while a plunge would see the stock gain -92.51% from current levels.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Figures show that Arcutis Biotherapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -7.43% over the past 6 months, with this year growth rate of 58.73%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 181.80%.
6 analysts offering their estimates for the company have set an average revenue estimate of 37.37M for the current quarter. 6 have an estimated revenue figure of 47.62M for the next ending quarter. Year-ago sales stood 32.83M and 13.53M respectively for this quarter and the next, and analysts expect sales will grow by 13.80% for the current quarter and 181.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -48.07% over the past 5 years. Earnings growth for 2024 is a modest 60.20% while over the next 5 years, the company’s earnings are expected to increase by 9.80%.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT)’s Major holders
Insiders own 2.18% of the company shares, while shares held by institutions stand at 111.37% with a share float percentage of 113.86%. Investors are also buoyed by the number of investors in a company, with Arcutis Biotherapeutics Inc having a total of 250.0 institutions that hold shares in the company. The top two institutional holders are JENNISON ASSOCIATES LLC with over 11.57 million shares worth more than $107.62 million. As of 2024-06-30, JENNISON ASSOCIATES LLC held 9.3712% of shares outstanding.
The other major institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, with the holding of over 10.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $93.04 million and represent 8.1021% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are PGIM Jennison Small Company Fd and Vanguard Total Stock Market Index Fund . As of Aug 31, 2024 , the former fund manager holds about 2.64% shares in the company for having 3.09 shares of worth $28.85 million while later fund manager owns 2.96 shares of worth $27.64 million as of Jun 30, 2024 , which makes it owner of about 2.53% of company’s outstanding stock.
